[Effect of apoptotic ovarian cancer cells induced by paclitaxel-cisplatin on antigen presentation function of DC].
OBJECTIVE
To explore wheather apoptotic ovarian cancer cells induced by paclitaxel-cisplatin could be cross-presented by antigen presenting cells and promote immune responses.


METHODS
DCs were generated from peripheral blood monocytes in RPMI1640 supplemented with GM-CSF and IL-4. After 6 days' incubation, DCs were further co-cultured with either apoptotic HO8910 cell lines induced by paclitaxel-cisplatin or control cells for four hours. Maturation of DCs was compared among different groups according to their surface markers through flow cytometry assay and their phagocytosis ability was evaluated by confocal microscopy scanning assay.


RESULTS
Apoptotic ovarian cancer cells induced by paclitaxel-cisplatincan were phagocytized more efficiently by DCs.Resulting is more cellularity and maturation of DCs in apoptotic cell-induced groups than control group (P<0.05).


CONCLUSIONS
Apoptotic ovarian cancer cells induced by paclitaxel-cisplatin exhibit strong immunogenicity, which in turn promote the maturation and antigen presentation of DCs.
Feng
Qin-Mei
QM
Renji Hospital, Shanghai Jiaotong University School of Medicine, China.
Wu
Xia
X
Wang
Ying
Y
Ge
Hai-Liang
HL
Di
Wen
W
D017951:Antigen Presentation / Q000276:immunology*; D017209:Apoptosis / Q000187:drug effects*; D002454:Cell Differentiation / Q000276:immunology; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology; D018613:Microscopy, Confocal; D010051:Ovarian Neoplasms / Q000276:immunology*; D017239:Paclitaxel / Q000494:pharmacology*; D010587:Phagocytosis / Q000276:immunology
D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017239:Paclitaxel; D002945:Cisplatin